Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Keloids
NCT05330078Phase 1Completed
- Sponsor
- University of California, San Diego
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in keloid comparing Botulinum toxin type A with Vehicle (Saline) (2 arms). Primary endpoint: Change in Keloid volume at 24 weeks. Started Mar 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
keloid
Beyond the preview
Go deeper on NCT05330078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330078.